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Abstract
Background: Human stem cells are cellular resources with outstanding potential for cell therapy.
However, for the fulfillment of this application, major challenges remain to be met. Of paramount
importance is the development of robust systems for in vitro stem cell expansion and differentiation.
In this work, we successfully developed an efficient scalable bioprocess for the fast production of
human neurons.
Results: The expansion of undifferentiated human embryonal carcinoma stem cells (NTera2/cl.D1
cell line) as 3D-aggregates was firstly optimized in spinner vessel. The media exchange operation
mode with an inoculum concentration of 4 × 105 cell/mL was the most efficient strategy tested,
with a 4.6-fold increase in cell concentration achieved in 5 days. These results were validated in a
bioreactor where similar profile and metabolic performance were obtained. Furthermore,
characterization of the expanded population by immunofluorescence microscopy and flow
cytometry showed that NT2 cells maintained their stem cell characteristics along the bioreactor
culture time.
Finally, the neuronal differentiation step was integrated in the bioreactor process, by addition of
retinoic acid when cells were in the middle of the exponential phase. Neurosphere composition
was monitored and neuronal differentiation efficiency evaluated along the culture time. The results
show that, for bioreactor cultures, we were able to increase significantly the neuronal
differentiation efficiency by 10-fold while reducing drastically, by 30%, the time required for the
differentiation process.
Conclusion: The culture systems developed herein are robust and represent one-step-forward
towards the development of integrated bioprocesses, bridging stem cell expansion and
differentiation in fully controlled bioreactors.
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Background
Many neurodegenerative disorders, such as Parkinson's
disease, are caused by the impairment or death of neurons
in the central nervous system [1]. In the future, it is hoped
that large numbers of stem cell-derived neurons will be
produced in culture with the purpose of being used in
clinical applications [2]. Hampering the faster implemen-
tation of the ambitious stem cell therapy technology,
there is still the need of efficient, robust and scalable bio-
processes for cell expansion and/or differentiation in vitro.
During the last five years, substantial progress has been
made towards this goal [3,4]. Stirred suspension systems
have been pioneered, by others and ourselves, as a prom-
ising in vitro system for stem cell expansion [5,6], embry-
oid body cultivation [7,8] and stem cell differentiation
into specific cell types [9]. These systems offer attractive
advantages of scalability and relative simplicity; stirring
provides a more homogenous culture environment and
allows the measurement and control of extrinsic factors
such as nutrient and cytokine concentration, pH and dis-
solved oxygen (pO2) [10].
Aiming to improve the yields of specific stem cell stages,
several culture parameters have been optimized, includ-
ing the agitation rate, cell inoculum concentration and
medium composition [3,4,11], and different culturing
approaches have been developed such as the use of micro-
carrier supports [5] and cell encapsulation [11]. Perfusion
and frequent feeding operation modes have been shown
to increase the expansion of mesenchymal stem cells [11],
embryonic stem cells [12,13] and mammary epithelial
stem cells [14], without compromising their stem cell per-
formance.
Computer-controlled bioreactors are particular advanta-
geous for process development by allowing the online
monitoring and control of specific culture parameters
(temperature, pH and pO2), ensuring a fully controlled
environment for stem cell cultivation. Oxygen-controlled
bioreactors have been used for culture of mouse and
human ESC-derived cardiomyocytes [7,15]. Gilbertson et
al [16] were the first group to use controlled conditions
for neural precursor cell culture as aggregates; the authors
report the successful expansion of mouse neural stem cells
in 500 mL bioreactors (temperature, pH and pO2 control)
while retaining the cell multilineage potential [16]. More
recently, this system was applied to the culture of human
neural precursor cells [17]. The expansion of various
human stem cell types in bioreactors under defined and
controlled conditions remains to be addressed. Future
challenges also include the combination of expansion and
directed differentiation steps in an integrated bioprocess
that will ultimately result in scale-up of well differentiated
cells to clinically relevant numbers.
Within this context, the present work focused the develop-
ment of a reproducible scalable system for the production
of human neurons derived from expanded and differenti-
ated stem cells. The human embryonal carcinoma cell line
NTera-2/cl.D1 (NT2) was the cellular system used because
it is a valuable model for both undifferentiated human
embryonic stem cells (hESCs) [18] and human neuronal
differentiation  in vitro [19]. In addition, the neurons
derived from this cell line have been successfully used in
transplantation studies in several mouse models and in
human stroke patients [20], providing also promising
material for cell therapy investigations in central nervous
system.
Herein, undifferentiated NT2 cells were cultivated as 3D-
aggregates in controlled stirred suspension conditions. In
order to improve the yields of stem cells, two parameters
were studied: (i) the inoculum concentration, as it has
been shown to be critical in enhancing cell aggregation
and culture profile [6], and (ii) the culture operation
mode, since it has been demonstrated that the feeding
strategy affects cell metabolism and consequently could
improve cell culture performance [11,15,21]. At the end,
the expansion of undifferentiated NT2 cells, followed by
directed neuronal differentiation were integrated in
stirred bioreactors with temperature, pH and pO2 control,
in an effort to develop a promising model system for the
production of human stem cell derivatives.
Results
With the goal of developing a robust and scalable system
for NT2 neuronal differentiation, both expansion and dif-
ferentiation steps were integrated in a fully controlled bio-
reactor process. Firstly, different strategies for expansion
of undifferentiated NT2 cells as 3-D aggregates were
screened in stirred spinner vessels; two parameters were
studied (i) the inoculum concentration and (ii) the cul-
ture operation mode, i.e., medium replenishing strategies.
Having the expansion of pluripotent NT2 cells optimized
and well characterized, the neuronal differentiation strat-
egy previously developed by our group [9], was integrated
and the overall bioprocess combined in the bioreactor.
Figure 1 summarizes the experimental outline used for
expansion and differentiation processes.
Effect of inoculum concentration in NT2 expansion
Three different cell inoculum concentrations were tested
in batch culture mode, using 125 mL spinners: 0.4, 1 and
4 × 105 cell/mL (SP-0.4B, SP-1B and SP-4B, respectively).
During the first 24 h of SP-1B and SP-4B cultures, cells
assembled into small 3D-aggregates (Figure 2A) ranging
from 40 to 65 μm. After this period, cells started to divide
and aggregate size increased up to 150 μm. The growth
curve and the calculated apparent growth rates are shownBMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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in Figure 2B and Table 1, respectively. SP-1B exhibited a
high apparent growth rate (0.51 ± 0.01 day-1) and the
highest FI in cell concentration (7.14 ± 0.86). Neverthe-
less, maximum cell density 6.64 (± 1.57) × 105 cell/mL
was only reached 6 days after inoculation, whereas in SP-
4B, a maximum of 8.48 (± 0.11) × 105  cell/mL was
achieved at day 3. From day 4 onwards of SP-4B culture,
cells started to detach from the aggregates (Figure 2A),
resulting in cell death (data not shown). Similar behavior
was observed for SP-1B culture upon day 7 of cultivation.
Concerning the SP-0.4 culture, cell aggregates were rare
and small throughout cultivation time (Figure 2A). In
fact, no effective cell growth was observed (Figure 2B) and
cell viability was low (data not shown).
Aiming to develop an efficient bioprocess for the fast pro-
duction of human neurons, cell number and culture time
were the parameters preferentially used to select the best
strategy. For SP-4B, the time needed to achieve Xmax was 2
times lower than for SP-1B, reaching similar Xmax values
(Table 1). Based on these results, SP-4B was chosen to be
further optimized and integrated with the neuronal differ-
entiation step.
Impact of operation mode in NT2 cell expansion
In all batch cultures there was a rapid decrease in cell den-
sity after the culture reached its maximum concentration
value (Figure 2A). Although no complete depletion of nei-
ther glucose nor glutamine was observed (Figure 3A, C),
this profile could be correlated to the exhaustion of other
essential nutrients and/or the progressive accumulation of
toxic metabolic waste products such as lactate and ammo-
nia (Figure 3B, D). In SP-4B, by the 4th day of cultivation,
the lactate and ammonia concentrations were already
21.9 mM and 3.1 mM, respectively (Figure 3B, D). In SP-
1B, these values were also high at day 7 of culture (27.2
mM and 4.2 mM for lactate and ammonia concentration,
respectively).
Aiming at prolonging the exponential growth phase and
improve the cell expansion, two additional operation
modes were tested. The first strategy consisted of a glucose
fed-batch operation mode (SP-4FB). In this strategy, cul-
ture was initiated at low concentration of glucose (1.4
mM) and the feeding was performed twice a day assuring
the maintenance of low levels of glucose throughout cul-
tivation time (see Methods section). The second strategy
(SP-4ME) was designed to simulate a perfusion system, in
which cells are kept in culture and the media is renovated
regularly. This was achieved by performing a daily partial
media exchange (50%) from the 3rd  cultivation day
onwards, as this time point corresponded to the growth
peak in the batch culture (Figure 2B, SP-4B).
For SP-4ME and SP-4FB cultures, the exponential growth
phase was extended until day 5 (Figure 3F), with a signif-
icant increase in Xmax, when compared to SP-4B (Table 1).
These differences are also reflected in cell metabolism, as
shown by the nutrient consumption and metabolite pro-
duction profiles (Figure 3E). The SP-4FB culture presented
the lowest specific rates of glucose consumption and lac-
tate production. The lower accumulation of lactate (16.5
Experimental outline for NT2 cell sampling and characterization during expansion (A) and differentiation (B) in fully controlled  bioreactors Figure 1 (see previous page)
Experimental outline for NT2 cell sampling and characterization during expansion (A) and differentiation (B) 
in fully controlled bioreactors. (A) In expansion runs, cells were harvested from days 0 (inoculum), 3 and 6 and immedi-
ately characterized by flow cytometry. Harvested cells were plated on glass coverslips and processed for immunofluorescence 
microscopy analysis after 2 days or plated in tissue culture flasks for induction of neuronal differentiation. For this, cultures 
were treated with retinoic acid (RA) for 5 weeks, splitted and further cultured in mitosis inhibitory (MI) conditions. After 12 
days in MI, the neurons were harvested, identified by immunofluorescence microscopy using neuronal markers and neuronal 
differentiation efficiencies were calculated. (B) In differentiation runs, the addition of RA was initiated at day 3 of bioreactor 
culture and prolonged for 3 weeks. Neurospheres were harvested at day 9, 16 and 23. The latest were analyzed by cryosection 
immunofluorescence microscopy. All neurosphere harvested were plated in static culture flasks and cultured in MI conditions. 
After 3 days, cultures were characterized by immunofluorescence microscopy and after 7 days and neuronal differentiation effi-
ciencies were calculated.
Table 1: Growth kinetics of NT2 cell expansion as 3D-aggregates 
using different culture strategies.
Strategy μ (day-1)F IX max (×105 cell/mL)
SP-0.4B n. a. n. a. 0.63 ± 0.11 *
SP-1B 0.51 ± 0.01 7.14 ± 0.86 * 6.64 ± 1.57
SP-4B 0.39 ± 0.02 2.12 ± 0.03 8.48 ± 0.11
SP-4FB 0.52 ± 0.06 4.30 ± 0.33 * 17.19 ± 1.30 *
SP-4ME 0.41 ± 0.06 4.56 ± 0.04 * 18.25 ± 0.18 *
BR-4ME 0.37 ± 0.03 4.10 ± 0.41 16.25 ± 0.16
Apparent growth rate (μ), fold increase (FI) and maximum cell 
concentration values (Xmax) of NT2 cells cultured in spinner vessel 
(SP) or in bioreactor (BR); with inoculum densities of 0.4 × 105 (SP-
0.4) 1 × 105 (SP-1) or 4 × 105 cell/mL (SP-4, BR-4); in batch (B), fed-
batch (FB) and media-exchange (ME) culture operation mode. Results 
are expressed as mean ± SEM from n = 2 independent experiments. n. 
a. - not applicable. *Indicates significant statistical difference (p-value < 
0.05) from the SP-4B mean values of μ, FI and Xmax by the one-way 
ANOVA analysis with a Scheffé post-hoc multiple comparison test.BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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Effect of inoculum concentration in NT2 cell expansion as 3D-aggregates Figure 2
Effect of inoculum concentration in NT2 cell expansion as 3D-aggregates. Cells were cultured in spinner vessels 
with inoculum concentrations of 0.4 (SP-0.4B, squares), 1 (SP-1B, circles) and 4 (SP-4B, triangles) ×105 cell/mL. Phase contrast 
photomicrographs of cultures samples visualized by day 1, day 3 and day 6 of cultivation. Scale bar: 100 μm (A). Growth curves 
expressed in terms of cell concentration; error bars denote standard deviation of average from 2 independent experiments 
(B).BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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Effect of culture operation mode on NT2 cell expansion as 3D-aggregates Figure 3
Effect of culture operation mode on NT2 cell expansion as 3D-aggregates. Cells were cultured in spinner vessels 
(SP) or in bioreactors (BR), with inoculum concentration of 4 × 105 cell/mL, using different operation modes: batch (SP-4B, 
black line and triangles), fed-batch (SP-4FB, dashed line and white triangles) and media exchange (SP-4ME, dashed line and black 
triangles, and BR-4ME, grey line and triangles). Concentrations of glucose (A), lactate (B), glutamine (C) and ammonia (D) 
presented in media during culture time. Specific rates of glucose consumption and lactate production shown over the course of 
exponential growth phase (E) (day 2- white bars, day 3- grey bars, day 4-striped bars, day 5- black bars). Growth curves 
expressed in terms of cell concentration; error bars denote standard deviation of average from 2 independent experiments 
(F).BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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mM at day 6, Figure 3B) in SP-4FB contributed to the high
apparent growth rate of this strategy (0.52 ± 0.06 day-1,
Table 1). Nevertheless, there was still a steeply decrease in
cell concentration after day 6 (Figure 3F) that may result
from the accumulation of other toxic metabolites, such as
ammonia, which reached values as high as in SP-4B (4.0
mM and 4.2 mM for SP-4FB and SP-4B cultures, respec-
tively, at day 6 of cultivation, Figure 3D).
Cell viability was calculated in term of cell lysis, translated
by the specific release rates of the intracellular enzyme
LDH (qLDH). For SP4-ME, the qLDH achieved were lower
(fold increase of 9.1) than those obtained for SP-4B and
SP-4FB (fold increase of 20.5 and 19.4, respectively)
throughout 6 days of cultivation, indicating that a lower
percentage of cell lysis occurred in the SP-4ME culture.
Despite no complete depletion of either glucose or
glutamine was observed in the strategies tested, cells in
SP4-ME were not continuously subjected to the accumu-
lation of toxic metabolites, which probably had a positive
effect on cell viability (Figure 3A-D).
Expansion and characterization of undifferentiated NT2 
cells in a bioreactor
From the results shown above, SP-4ME was the most
promising culture strategy for expansion of undifferenti-
ated stem cell. The next step was the implementation of
this strategy in a fully controlled 125 mL bioreactor, BR-
4ME.
The growth curve obtained for the bioreactor run BR-4ME
was comparable to the one obtained for the medium
exchange operation mode in spinner SP-4ME; similar
apparent growth rates and maximum concentrations were
obtained (Figure 3F, Table 1). NT2 cells expanded in the
bioreactor for 6 days were characterized in terms of
pluripotency, undifferentiated phenotype and differentia-
tion potential. The expression of stem cell markers (Oct-4,
TRA-1-60, SSEA-4) and nestin, an intermediate filament
protein associated with undifferentiated phenotype of
NT2 cells [22], was detected during exponential growth
phase (day 3) and at day 6 (Figure 4A). This labeling pat-
tern was similar to the cell inoculum (day 0).
Moreover, in addition to the expression of stem markers
analysis, the expanded cells ability to differentiate into
neurons was also confirmed. For that purpose, cells were
collected at 3 time points (day 0, 3 and 6) and induced to
differentiate into neurons using the standard static differ-
entiation protocol [23]. After treatment with RA and fur-
ther cultivation in MI medium, the neuronal
differentiation efficiency (defined as the ratio between the
number of neurons obtained and the number of cells har-
vested from the bioreactor, see Methods section) was sim-
ilar for all culture samples, presenting values in the range
typically obtained for the static differentiation protocol
(3.3 ± 0.2%) [9]. The differentiated neurons were identi-
fied by βIII-Tub and MAP2 positive staining (Figure 4B).
Overall, these results showed that NT2 cells maintained
their pluripotency, undifferentiated phenotype, and dif-
ferentiation potential along expansion in the bioreactor.
Integrating expansion and neuronal differentiation of NT2 
cells in the bioreactor
Once the expansion of pluripotent NT2 cells was adapted
and characterized in the bioreactor system, we further
integrated the neuronal differentiation step according to
Serra et al [9]. Neuronal differentiation was induced by RA
addition when cells achieved the middle of the exponen-
tial growth phase at day 3 (Figure 3C). Flow cytometry
analysis of cell populations showed that the levels of Oct-
4 (94.8% positive cells) and Tra-1-60 (88.7% positive
cells) obtained for the inoculum were kept at day 3 of the
bioreactor culture (97.2% and 94.6% Oct-4 and Tra-1-60
positive cells, respectively), confirming that the stem cell
population was maintained at this time point.
Throughout differentiation, the aggregate size increased,
reaching average diameters of 150 ± 40, 309 ± 94 and 458
± 44 μm after 1, 2 and 3 weeks of RA treatment, respec-
tively (Figure 5A, B, C, Table 2). The aggregate shape
became uniform, forming compact and spherical struc-
tures (Figure 5B, C). Immunofluorescence microscopy of
aggregate cryosections showed that these were neuro-
spheres, composed of precursors (nestin-positive) and
differentiated neurons (βIII-Tub-positive), the latest dis-
tributed preferentially at the surface (Figure 5C1).
After 9, 16 and 23 days of bioreactor culture (1, 2 and 3
weeks of neuronal differentiation, respectively), neuro-
spheres were harvested and cultured for 7 days, on PDL-
MG coated flasks, in MI medium, to allow cell migration
and inhibit cell proliferation. One day post-seeding, the
presence of neurites surrounding the neurospheres was
more pronounced on cultures harvested at day 23 (Figure
5F), while on neurospheres harvested earlier, cells with
flattened morphology predominated (Figure 5D). Three
days post-seeding, the cell culture composition was ana-
lyzed by immunofluorescence microscopy (Figure 5G, H,
I). Cultures derived from neurospheres harvested at day
23 were richer in neurons (βIII-Tub-positive staining) and
presented more developed neuritic networks than the
neurospheres harvested at day 16 (Figure 5H, I). A
reduced number of βIII-Tub-positive cells was detected in
cultures derived from neurospheres collected at day 9, in
which nestin-positive cells predominated (Figure 5G).
The estimated neuronal differentiation efficiency was 0.13
± 0.06% and 17.2 ± 2.2% for cultures derived from neuro-
spheres harvested at day 9 and 16 (Table 2). The resultsBMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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Characterization of NT2 cells expanded as 3D-aggregates Figure 4
Characterization of NT2 cells expanded as 3D-aggregates. Immunofluorescence images of cells from the inoculum 
(day 0) and collected from the bioreactor culture (day 3 and day 6). Immunolabeling of Oct-4, TRA-1-60, SSEA-4 (green) and 
nestin (red). Nuclei are labeled with DAPI (blue) (A). Immunofluorescence images of differentiated cultures derived from the 
inoculum (day 0) and from the bioreactor culture (day 3 and day 6). Neurons labeled with βIII-Tub and MAP2 (green) (B). 
Nuclei were stained with DAPI (blue). Scale bars: 100 μm.BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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obtained until day 16 were similar to the ones described
for the spinner culture [9], both in culture profile and dif-
ferentiation efficiency, proving that the integrated culture
strategy was successfully implemented in the bioreactor.
Moreover, by extending the RA treatments for an addi-
tional week, a significant increase in the yield of neuronal
differentiated cells was obtained (neuronal differentiation
efficiency of 37.4 ± 0.9%, Table 2).
Discussion
To fully fulfill the expectations raised by cell therapy it is
urgent to develop robust and totally controlled culture
systems, specially designed for the production of high
numbers of differentiated and well characterized cells,
expanded as fast and pure as possible. In the present
study, we successfully developed a bioprocess for the
rapid production of human neurons using fully control-
led stirred tank bioreactors (125 mL). This was accom-
plished by integrating human NT2 cell expansion and
differentiation in a two-step bioprocess.
In this particular study, an ideal expansion strategy should
assure the fast production of high numbers of stem cells
without compromising their potential. We demonstrated
that, along expansion as 3-D aggregates, NT2 cells main-
tained their pluripotent and undifferentiated phenotype
as well as the ability to differentiate into neurons. Differ-
ent bioreaction parameters, including cell inoculum con-
centration and culture operation mode were studied. The
results indicate 4 × 105 cell/mL as the most adequate inoc-
ulum strategy to be integrated with the differentiation
step, as it allowed higher cell densities in less culture time
contributing to a fast overall process. However, the feasi-
bility of starting the cultures with inoculum concentra-
tions as lower as 1 × 105 cell/mL looks promising for
specific clinical applications in which the starting material
is a limiting factor. Although lower inoculation concentra-
tions have been used to expand undifferentiated murine
embryonic stem cells as aggregates [6,24], NT2 cell prolif-
eration could not be achieved when 4× 104 cell/mL were
used. This difference in cell behavior may reflect the dis-
tinct cell origins, as NT2 are pluripotent human embryo-
nal carcinoma stem cells, derived from teratocarcinomas
[23], that closely resemble the human embryonic stem
cells derived from the blastocyst inner cell mass [25].
By using a fed-batch strategy, where low levels of glucose
were maintained in culture, it was possible to enhanced
glucose metabolism efficiency with a concomitant
improvement of the FI in cell concentration and increase
of culture lifespan. This strategy may have minimized the
toxicity effect associated with lactate accumulation, as
reported previously for several animal cell cultures
[21,26]. Nevertheless, the accumulation of other toxic
metabolites, including ammonia, resulted in an increase
in cell death. The possible depletion of nutrients (others
than glucose and glutamine) as well as the exhaustion of
essential small molecules, namely growth factors, not
replenished in the glucose fed-batch strategy, may have
contributed to arrest cell growth. The media exchange
mode overcame these drawbacks, being the most efficient
strategy to enhance undifferentiated stem cell cultivation,
as shown by the higher cell densities and higher culture
viability obtained throughout the cultivation time. There-
fore this strategy was chosen for implementation in the
controlled bioreactor in which stem cell expansion was
successfully reproduced, confirming the robustness of the
process. Media exchange and perfusion strategies have
been used previously for adult stem cell cultivation [3,9]
and human embryoid bodies [13]. In order to achieve
higher expansion ratios, as those obtained for the expan-
sion process as aggregates of murine embryonic stem cell
[6,24] and human neuronal precursor cell [17], serial pas-
sage with addition of fresh media can be further included.
By incorporating both expansion and differentiation steps
in an integrated bioprocess, this strategy also assures the
feasibility of expanding human differentiated neurons
derived from a continuous source of pluripotent stem
cells. The system described herein allows for obtaining
well differentiated neurons after 2 weeks of differentia-
tion, as well as higher yields of neurons for a later culture
time. Importantly, when compared to well established
static differentiation protocols, this methodology drasti-
cally enhanced the neuronal differentiation efficiency of
NT2 cells and reduced the time needed for differentiation
Table 2: Characterization of NT2 neurospheres cultured in a fully controlled bioreactor.
Neurospheres
Time of harvesting (day) 9 16 23
Duration of retinoic acid treatment (week) 1 2 3
Neurosphere size (μm) 150 ± 40 309 ± 94 458 ± 44
Differentiation efficiency 0.13 ± 0.06 17.2 ± 2.2 37.4 ± 0.9
Neurosphere size and neuronal differentiation efficiency are expressed as mean ± SEM from n = 2 independent bioreactor experiments.BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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process; for a differentiation time of 23 days in the biore-
actor culture a 10-fold improvement in yield was observed
over the static culture protocols lasting 35 days [23].
In this work, the expansion and differentiation of NT2
cells was successful validated in computer-controlled bio-
reactors. In future, further optimizations can be attempted
aiming to determine the optimal conditions (pH, pO2 and
temperature) to grow and differentiate NT2 cells. So far,
some studies have demonstrated that low pO2 decreases
the rate of stem cell differentiation and enhances stem cell
proliferation [27]. Nieruebuegge et al. also reported a sig-
nificant increase in final cell number as well as an
improvement of cardiac-enriched genes in hEBs cultures
under hypoxic conditions (pO2 = 4%) [7]. A recent study
reports that rat mesenchymal stem cell differentiation is
Neuronal differentiation of NT2 cells in a fully controlled bioreactor Figure 5
Neuronal differentiation of NT2 cells in a fully controlled bioreactor. Neuronal differentiation was induced by addi-
tion of retinoic acid (RA) from day 3 onwards (RA treatments). Phase contrast photomicrographs of neurospheres harvested 
at day 9 (A), day 16 (B) and day 23 (C) of the bioreactor culture. By day 23, neurosphere composition was analyzed by cryo-
section immunofluorescence microscopy - double labeling of nestin (red) and βIII-Tub (green) (C1). Harvested neurospheres 
were further cultured in mitotic inhibitory (MI) conditions, on poly-D-lysine and Matrigel-coated surfaces. Cultures were visu-
alized by phase contrast microscopy 1 day after plating (D,E,F) and characterized by immunofluorescence microscopy 3 days 
after plating (G,H,I). Double labeling of nestin (red) and βIII-Tub (green). Phase contrast and immunofluorescence images of 
cultures derived from neurospheres harvested at day 9 (D,G), day 16 (E,H) and day 23 (F,I). Scale bars: 100 μm.BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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enhanced at lower temperatures (32°C) than in 37°C
conditions [28].
Conclusion
In this work, a scalable and efficient two-step bioprocess
for the generation of human NT2-derived neurons was
developed in a fully controlled bioreactor, allowing con-
tinuous monitoring, non-invasive sampling and charac-
terization. By integrating a fast expansion step with an
efficient differentiation process, this strategy significantly
reduced the time and improved the yields of the neuronal
differentiation, when compared to the standard static dif-
ferentiation protocols.
The controlled bioprocess developed herein can be adapt-
able to other cell types, including hESCs and iPS, repre-
senting a strong and promising starting point for the
development of novel technologies for the production of
differentiated derivatives from pluripotent cells.
Methods
Cell culture
NTERA-2/cl.D1 cells (NT2) were obtained from the
CNDR, University of Pennsylvania School of Medicine.
Undifferentiated NT2 cells were routinely cultivated in
standard tissue culture flasks (Nunc) and maintained in
OptiMEM medium (Invitrogen) supplemented with 5%
(v/v) of fetal bovine serum (FBS, Hyclone) and 100 U/mL
of penicillin- streptomycin (P/S, Invitrogen), according to
method described at Brito et al.[29].
Stirred suspension culture
Undifferentiated NT2 cell expansion in spinner vessels
Undifferentiated NT2 cells (passage 60-62) were cultured
as 3D-aggregates in 125-mL spinner vessels (Wheaton)
equipped with a ball impeller and maintained at 37°C
and 5% CO2 for up to 7 days. The agitation rate was
increased during cultivation in order to avoid aggregate
clumping and to control aggregate size (day 0 to 2 - 60
rpm, day 2 to 3 - 70 rpm, day 3 to 4 - 80 rpm, day 4
upwards - 90 rpm). Two independent experiments were
performed for each expansion strategy.
Inoculum Concentration Experiments
Cells were cultured in a batch operation mode in Dul-
becco's Modified Eagle's Medium- High Glucose (DMEM-
HG, 25 mM glucose) (Invitrogen) supplemented with
10% (v/v) FBS and 100 U/mL of P/S (complete DMEM-
HG). The cell inoculum concentrations evaluated were:
0.4 × 105, 1 × 105 and 4 × 105 cell/mL; for an easier reading
the nomenclature used was SP-0.4B, SP-1B and SP-4B,
respectively. In SP-0.4B and SP-1B, cells were cultured in
75 mL of medium at 50 rpm during the first 4-8 h, to pro-
mote cell aggregation.
Culture Operation Mode Experiments
Glucose fed-batch and medium exchange culture opera-
tion modes were performed using an inoculum cell den-
sity of 4 × 105 cell/mL; the nomenclature used for these
experiments were SP-4FB (SP- spinner, FB- fed-batch) and
SP-4ME (SP- spinner, ME- media exchange), respectively.
In SP-4FB, the culture medium was DMEM-Base (Sigma)
supplemented with 10% (v/v) FBS, 4 mM of glutamine
(Invitrogen), 100 U/mL P/S and 1.4 mM of glucose
(Merck). During culture time, glucose concentration was
monitored twice a day and maintained at lower levels
(<1.4 mM); refeeds were performed accordingly to the
consumption rates (calculated from 2 consecutive sam-
ples). SP-4ME was cultured in similar conditions to those
described for SP-4B, except that medium was partially
exchanged daily from the day 3 onwards as follows: fifty
percent of culture media was collected in sterile condi-
tions and centrifuged at 200 × g for 5 min; the supernatant
was discarded and the recovered cell aggregates gently
resuspended in an equivalent volume of pre-warmed
complete DMEM-HG.
For all spinner cultures, sampling (2.5 mL) was performed
4 h after inoculation and daily from then on. Cell aggre-
gates were monitored under an inverted microscope
(Leica DM IRB). Cell concentration, metabolite concen-
tration and lactate dehydrogenase activity were analyzed
as described below.
NT2 culture in a fully controlled bioreactor
To ensure fully controlled cell culture environment, a
stirred tank bioreactor [30] equipped with ball impeller
and pH and dissolved oxygen (pO2) measuring probes
(Mettler-Toledo) was used for the expansion and differen-
tiation of NT2 cells. The pH was kept at 7.2 by injection of
CO2 and addition of base (NaOH, 0.2 M). The pO2 was
maintained at 25% via surface aeration. The temperature
was kept at 37°C by water recirculation in the vessel jacket
controlled by a thermocirculator module. Data acquisi-
tion and process control were performed using MFCS/Win
Supervisory Control and Data Acquisition (SCADA) soft-
ware (Sartorius-Stedim, Germany).
NT2 cell expansion
The SP-4ME experiment was reproduced in the bioreactor
system, using undifferentiated NT2 cells with 60-62 pas-
sages in static conditions. Moreover, cells used for the
inoculum (day 0) and at days 3 and 6 of cultivation in the
bioreactor, were characterized using immunofluorescence
tools and the neuronal differentiation potential evaluated
(see below).
NT2 neuronal differentiation
Undifferentiated NT2 cells with up to 62 passages in static
conditions were expanded in the bioreactor, in completeBMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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DMEM-HG, using an inoculum concentration of 4 × 105
cell/mL. Differentiation was initiated in the middle of the
exponential phase (day 3), following the differentiation
protocol developed by Serra et al [9]. Briefly, neuronal dif-
ferentiation was induced by addition of retinoic acid (RA,
Sigma) to the culture media, at a final concentration of 10
μM. A 50% media exchange was performed 3 times a week
on a regular basis for up to 24 days. Two bioreactor inde-
pendent experiments were performed.
Samples were collected from the bioreactor at 3 time
points: day 9, 16 and 23 (corresponding to 1, 2 and 3
weeks of differentiation process). Cell concentration and
neurosphere size were determined and culture was charac-
terized using immunofluorescence microscopy. Neuro-
spheres harvested at the referred time points were
transferred to coverslips or culture flasks (5 × 104 cell/
cm2) coated with poly-D-lysine (PDL, Sigma) and
Matrigel (MG, Becton-Dickinson) and cultured for up to 7
days in mitosis inhibitor (MI) medium: DMEM-HG sup-
plemented with 5% FBS, 100 U/mL of P/S, 1 μM cytosine
arabinosine (Sigma), 10 μM fluorodeoxyuridine (Sigma)
and 10 μM uridine (Sigma). Neurons were selectively
trypsinized [22,23] using a 0.015% Trypsin-EDTA solu-
tion (prepared from Trypsin-EDTA 1X, liquid 0.05%
Trypsin, Invitrogen), counted and transferred to coverslips
coated with PDL and MG for characterization by immu-
nocytochemistry. Neuronal differentiation efficiency was
defined as the ratio between the number of neurons
obtained after 7 days of culture in MI medium and the
total amount of cells harvested at the 3 different harvest-
ing times.
Analytical methods
Cell concentration determination
Cell aggregates were dissociated by a 2 min incubation
with Trypsin-EDTA (0.05%) at 37°C followed by cell
resuspension in complete DMEM-HG. Cell density was
assessed using a Fuchs-Rosenthal haemocytometer
(Brand, Wertheim, Germany) and cell viability estimated
by the standard trypan blue exclusion test.
Aggregate diameter
Aggregate size in each culture sample was determined
using a micrometer coupled to an inverted microscope
(Leica, DM IRB). Two perpendicular diameters of a mini-
mum of 15 aggregates were measured and the average
diameter was calculated. Aggregates less than 20 μm in
diameter (generally cell doublets or triplets) were not con-
sidered for calculations as they represent a small percent-
age of the total cell number in culture.
Lactate dehydrogenase activity
Lactate dehydrogenase (LDH) activity from the culture
supernatant was determined as an indirect way of assess-
ing cell death. LDH activity was determined by following
spectrophotometrically (at 340 nm) the rate of oxidation
of NADH to NAD+ coupled with the reduction of pyruvate
to lactate. The specific rate of LDH release (qLDH, U.day-
1.cell-1) was calculated for every time interval using the
following equation: qLDH = ΔLDH/(Δt ΔXV), where ΔLDH
(U) is the change in LDH activity over the time period Δt
(day) and ΔXv (cell) is the average of total cells during the
same time period. The cumulative value qLDHcum was esti-
mated by qLDHcum i+1 = qLDH i + qLDH i+1. The fold increase
of the specific LDH release rates achieved throughout 6
days of cultivation were determined by calculating the
ratio between the values of qLDHcum obtained at day 6 and
day 0. These values indirectly represent the fold increase
in cell lysis obtained within 6 days of culture.
Metabolite analysis
Glucose (GLC), lactate (LAC) and glutamine (GLN) con-
centrations in the culture medium were analyzed using an
YSI 7100MBS (YSI Incorporated, USA). Ammonia was
quantified enzymatically using a commercially available
UV test (Roche, Germany).
The specific metabolic rates (qMet., mol.day-1.cell-1) were
calculated using the equation: qMet. = ΔMet/(Δt ΔXv), where
ΔMet (mol) is the variation in metabolite concentration
during the time period Δt (day) and ΔXv (cell) the average
of adherent cells during the same time period.
Apparent growth rate and fold increase in cell expansion
Apparent growth rates and fold increase parameters were
calculated for all expansion cultures. Apparent growth
rates (μ, day-1) were calculated using a first order kinetic
model for cell expansion: dX/dt = μX, where t (day) is the
culture time and × (cell) is the value of viable cells for a
specific t. The μ values were estimated applying the model
to the slope of the curves during the exponential phase.
The fold increase in cell expansion (FI) was defined as the
ratio XMAX/X0, where XMAX is the peak cell density (cell/
mL) and X0 is the inoculation cell density (cell/mL).
Differentiation potential
To assess the neuronal differentiation potential along the
expansion assays, 2.3 × 106 cells were collected from the
suspension cultures and plated in a T75 flask (Nunc) (Fig-
ure 1). NT2 cells were differentiated into post-mitotic neu-
rons according to Pleasure et al [23]. Briefly, cells were
cultured for 5 weeks in complete DMEM-HG supple-
mented with 10 μM RA. Cells were splitted at 1:4.5 ratio
and cultured in MI medium for 12 days. After this period,
neurons were selectively trypsinized, as described above,
counted and transferred to coverslips coated with PDL
and MG for characterization by immunocytochemistry.
Neuronal differentiation efficiency was defined as the
ratio between the number of neurons obtained after cul-BMC Biotechnology 2009, 9:82 http://www.biomedcentral.com/1472-6750/9/82
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ture in MI medium and the total amount of cells harvested
after RA treatments.
Immunofluorescence microscopy
In expansion cultures, cell aggregates were collected at day
3 and 6, dissociated using Trypsin-EDTA (0.05%) at 37°C
followed by cell resuspension in complete DMEM-HG,
and transferred to glass coverslips. Three days after plat-
ing, cultures were characterized. In differentiation assays
neurospheres were harvested from the bioreactor cultures
at day 9, 16 and 23, and processed for cryosection or
transferred to coverslips coated with PDL and MG (see
Figure 1).
Cells in coverslips were washed in PBS with 0.5 mM
MgCl2 and fixed in 4% (w/v) paraformaldehyde solution
in PBS with 4% (w/v) sucrose, for 20 min. For cryosection,
neurospheres were washed in PBS, transferred to a tissue
protecting compound (Tissue Teck, OCT™ Compound)
and frozen at -80°C. Ten μm sections, obtained using a
cryostat (Leica), were rehydrated with PBS and fixed in
methanol, at -20°C, for 10 min. After fixation, the same
procedure was followed for cryosections and coverslips.
For staining intracellular epitopes, cells were permeabi-
lized with 0.1% (w/v) Triton X-100 (TX-100) in PBS, for
15 min. After 1 h in blocking solution (0.2% (w/v) fish
skin gelatin in PBS), cells were incubated with primary
antibody for 2 h. The coverslips were washed 3 times with
PBS and overlaid with secondary antibody for 1 h. Pri-
mary and secondary antibodies were diluted in 0.125%
(w/v) fish skin gelatin in PBS with 0.1% (w/v) TX-100.
Samples were mounted in ProLong mounting medium
(Molecular Probes), supplemented with DAPI for nucleus
staining. For surface epitopes staining, cells were not per-
meabilized with TX-100. Samples were visualized using a
fluorescence microscope (Leica DMRB).
Primary antibodies used were: mouse anti-tumor related
antigen-1-60 (Tra-1-60) (Santa Cruz Biotechnology),
mouse anti-stage specific embryonic antigen-4 (SSEA-4)
(Santa Cruz Biotechnology), mouse anti-Oct-4 (Santa
Cruz Biotechnology), mouse anti-nestin (Chemicon),
mouse anti-type III β-tubulin (βIII-Tub) (Chemicon),
mouse anti-microtubule associated protein 2A and 2B
(MAP2) (Chemicon). The secondary antibodies were goat
anti-mouse IgM-AlexaFluor488, goat anti-mouse IgG-
AlexaFluor 594, goat anti-mouse IgG-AlexaFluor 488 and
rabbit anti-mouse IgG-AlexaFluor 594 (Invitrogen).
Flow cytometry
Cells used for the inoculum (day 0) and from day 3 of the
bioreactor expansion culture were dissociated into single
cells and analyzed by flow cytometry (Figure 1). Samples
were fixed in CytofixCytoperm reagent (BD Pharmigen)
for 10 min, blocked with 1% BSA in PBS at 4°C for 30 min
and, in the case of intracellular antigens, permeabilized
with 1% TX-100 for 10 min. Primary antibodies were
mouse anti-Tra-1-60 and anti-Oct-4. Secondary antibod-
ies were anti-mouse IgM-AlexaFluor488 and anti-mouse
IgG-AlexaFluor488. Ten thousand events were registered
per sample with a CyFlow® space (Partec) instrument,
using the appropriate scatter gates to avoid cellular debris
and aggregates. A cell was considered to be positively
stained if the measured fluorescence intensity exceeded
the signal obtained by cells incubated with an isotype
control antibody (Santa Cruz Biotechnology).
Statistical analysis
For each spinner and bioreactor assays, two independent
experiments were performed. The results were expressed
as the mean ± standard deviation. The statistical test used,
One-way ANOVA, was performed in SPSS 13.0 for Win-
dows for a level of confidence of 95% (a = 0.05) followed
by the Scheffé multiple comparison test.
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